Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer.

Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Aflibercept, EYLEA was launched in China in 2018. By July 2022, Bayer AG is the only manufacturer in the Chinese Aflibercept market.

According to CRI’s market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY238 million in 2021. The annual growth rate in 2021 was 116%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of aflibercept in China is 206% from 2018 to 2021.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2023 to 2026. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME.

However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low.

The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.

Qilu Pharmaceutical, a local Chinese pharmaceutical company, received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for aflibercept intravitreal injection in April 2022, which is the first biosimilar application for aflibercept in China.

According to CRI’s market research, a number of other pharmaceutical companies in China are in the process of genericizing aflibercept, such as Clover Biopharmaceuticals’ aflibercept intraocular injection, which is in the clinical phase of application, and Shandong Boan Biotechnology Co.

It is expected that the generic version of aflibercept will enter the Chinese market in the next five years, but it is unlikely to have a significant impact on Bayer’s original drug in the short term.

Topics Covered:

• The impact of COVID-19 on China’s aflibercept market
• Sales value and volume of China’s aflibercept 2016-2020
• Competitive landscape of China’s aflibercept market
• Prices of aflibercept in China
• Prices of aflibercept in China by regions and manufacturers
• Analysis on factors affecting the development of China’s aflibercept market
• Prospect of China’s aflibercept market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Aflibercept

1.1 Indications for Aflibercept

1.2 Development of Aflibercept in China

1.3 Governmental Approval of Aflibercept in China

1.4 The Impact of COVID-19 on Aflibercept sales in China

2 Sales of Aflibercept in China, 2018-2021

2.1 Sales Value of Aflibercept

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Aflibercept

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Aflibercept by Dosage Form in China, 2018-2021

2.3.1 Intraocular Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Aflibercept Manufacturers in China, 2018-2021

3.1 Analysis of Market Share of Major Aflibercept Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Bayer AG

3.2.1 Enterprise Profile

3.2.2 Sales of EYLEA (Bayer’s Aflibercept) in China

4 Prices of Aflibercept for Different Manufacturers in China, 2021-2022

4.1 Bayer AG (EYLEA)

4.2 Others

5 Prospect of Chinese Aflibercept drug Market, 2022-2031

5.1 Influential Factors of Chinese Aflibercept Market Development

5.1.1 The Impact of COVID-19 on Chinese Aflibercept Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

List of Charts

Chart Aflibercept Drugs Approved by Chinese Government, by 2022

Chart Sales Value of Aflibercept in China, 2018-2021

Chart Sales Value of Aflibercept in Regions of China, 2018-2021 (Unit: CNY thousand）

Chart Sales Volume of Aflibercept in China, 2018-2021

Chart Sales Volume of Aflibercept in Regions of China,2018-2021

Chart Sales value and volume of aflibercept intravitreal injection in China 2018-2021

Chart Market Share of Aflibercept Manufacturers by Sales Value in China, 2018-2021

Chart Market Share of Aflibercept Manufacturers by Sales Volume in China, 2018-2021

Chart Profile of Bayer AG

Chart Sales Value of Bayer AG’s Aflibercept in China, 2018-2021

Chart Sales Volume of Bayer AG ‘s Aflibercept in China, 2018-2021

Chart EYLEA sold in the Chinese market

Chart Prices of BAYER AG’s Aflibercept (EYLEA ®) in Parts of China, 2021

Chart Forecast on sales of aflibercept in China 2022-2026

The post Investigation Report on China’s Aflibercept Market 2022-2031 first appeared on CRI Report.

According to CRI’s market research, the sales of Dasatinib have increased year by year from 2016 to 2020, with the most significant growth in 2018. The annual growth rate is 48.72 % from CNY51 million in 2017 to CNY75 million in 2018. The main reason for the increase is that China has undertaken an effort to cut healthcare costs, requiring insurance to cover 70% of costs since the national drug price negotiations in 2017. The CAGR of Dasatinib sales in 2016-2020 is 28.55%.

CRI analyzes that its sales will have an upward trend from 2021 to 2025 as the Chinese Dasatinib market expands. At present, 3 companies in China are in the approval stage of Dasatinib generic drugs. After the success of the approvals, the competition in the Chinese Dasatinib market will become more intense and the price will be less than before. Hence, the sales volume will increase accordingly. In addition, Dasatinib has been approved for 4 indications internationally, and only 2 indications have been approved in China. The number of indications approved in China is likely to increase, then sales still have the potential to increase.

Topics Covered:
-The impact of COVID-19 on China’s Dasatinib market
– Sales value of China’s Dasatinib 2016-2020
– Competitive landscape of China’s Dasatinib market
– Prices of Dasatinib in China
– Prices of Dasatinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dasatinib market
– Prospect of China’s Dasatinib market from 2021 to 2025

The post Investigation Report on China’s Dasatinib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, from 2016 to 2019, Abiraterone’s sales in the Chinese market have shown an upward trend. In 2017, the price of Abiraterone dropped and it was included in China’s national medical insurance. Therefore, the sales of Abiraterone in the Chinese market increased the most significantly from 2017 to 2019. The annual sales revenue in 2019 is CNY566.84 million, which increased over 30 times compared to that in 2016. The outbreak of the COVID-19 epidemic in 2020 has impacted the overall diagnosis and treatment business of Chinese hospitals, so the sales value of Abiraterone in the Chinese market declined slightly in 2020. The CAGR of Abiraterone sales value in the Chinese market from 2016 to 2020 is 140.7%.

CRI analyzes that from 2021 to 2025, Abiraterone’s sales in China will continue to grow as the improvement of COVID-19 epidemic. According to data from China National Cancer Registration Institute, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to rise, and its sales will also increase.

Topics Covered:
-The impact of COVID-19 on China’s Abiraterone market
– Sales value of China’s Abiraterone 2016-2020
– Competitive landscape of China’s Abiraterone market
– Prices of Abiraterone in China
– Prices of Abiraterone in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Abiraterone market
– Prospect of China’s Abiraterone market from 2021 to 2025

The post Investigation Report on China’s Abiraterone Market 2021-2025 first appeared on CRI Report.

Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy. Its product, developed by Abolis, was approved by the FDA in 2005 and was approved in China in 2008. By 2020, there are 34 manufacturers in China’s Paclitaxel market, with Nanjing Luye Pharmaceutical Co., Ltd. accounting for the most market share in the Chinese Paclitaxel market.

According to CRI’s analysis, the sales of China’s Paclitaxel market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital’s overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers. With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.

CRI analyzes that the Paclitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer. Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.

Topics Covered:

-The impact of COVID-19 on China’s Paclitaxel market
– Sales value of China’s Paclitaxel 2016-2020
– Competitive landscape of China’s Pacilitaxel market
– Prices of Paclitaxel in China
– Prices of Paclitaxel in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Paclitaxel market
– Prospect of China’s Paclitaxel market from 2021 to 2025

Global Anticoagulation Market—Forecast till 2027

The post Investigation Report on China’s Paclitaxel Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY 110 million in 2020. The annual growth rate in 2020 was 105.1%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of Aflibercept in China is 264% in 2018 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2021 to 2025. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME. However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low. The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.

Topics Covered:
-The impact of COVID-19 on China’s aflibercept market
– Sales value and volume of China’s aflibercept 2016-2020
– Competitive landscape of China’s aflibercept market
– Prices of aflibercept in China
– Prices of aflibercept in China by regions and manufacturers
– Analysis on factors affecting the development of China’s aflibercept market
– Prospect of China’s aflibercept market from 2021 to 2025

The post Investigation Report on China’s Aflibercept Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Ibrutinib entered the Chinese market, the sales value of Ibrutinib in China has increased from CNY48,600 in 2017 to CNY 345.5 million in 2020. In 2020, the growth rate was 38.2%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of Ibrutinib in China is 1823% in 2017 to 2020%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Ibrutinib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to price reduction and market expansion. Currently, Ibrutinib has three approved indications. In 2020, the latest approved indication was included in the national medical insurance catalog, while the other two had been included in the catalog in 2018. As all indications can take advantage of the insurance reimbursement, the usage rate of Ibrutinib will increase among the patients. Moreover, with the emergence of other BTK inhibitor drugs, the price of Ibrutinib may continue to decrease, which will lead to a rise in sales. On the other hand, China approves fewer indications for Ibrutinib than other countries do. Therefore, the number of approved indications has the potential to increase, which means the market will keep expanding in the future.

Topics Covered:
-The impact of COVID-19 on China’s Ibrutinib market
– Sales value and volume of China’s Ibrutinib 2016-2020
– Competitive landscape of China’s Ibrutinib market
– Prices of Ibrutinib in China
– Prices of Ibrutinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Ibrutinib market
– Prospect of China’s Ibrutinib market from 2021 to 2025

The post Investigation Report on China’s Ibrutinib Market 2021-2025 first appeared on CRI Report.